Syntara Limited · ASX:SNT
Syntara — Q1 2025 Earnings Presentation
11 slides from Syntara's earnings presentation, May 1, 2025
Slide 1: March Quarter Shareholder Update
For personal use only ™ March Quarter Shareholder Update Gary Phillips, CEO 01 May 2025
Slide 2: Forward looking statement
Forward looking statement For personal use only This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cau
Slide 3: Quarterly Shareholder Report | March 2025
Quarterly Shareholder Report | March 2025 For personal use only • SNT-5505 myelofibrosis latest interim data read out accepted for presentation at European Hematology Association (EHA) 2025 Congress in June • Skin scarring program advanced • New imaging analysis reveals biological and structural nor
Slide 4: Shareholders & cash
Shareholders & cash Financial Information (ASX: SNT) Share Price & Volume - YTD For personal use only Share price – 30 April 2025 $0.056 Price (AUD) 0.1 0.09 Market cap A$91.0m 0.08 0.07 Cash balance (31 Mar 2025) A$18.0m 0.06 0.05 0.04 Enterprise value A$73.0m 0.03 0.02 0.01 0 Volume Institutional
Slide 5: Myelofibrosis
Myelofibrosis A rare type of bone marrow cancer that disrupts the body's normal production of blood cells For personal use only Key Facts Primary Myelofibrosis is Current standard SNT-5505 characterised by a build up of scar of care (SoC): - JAK inhibition In contrast to SoC tissue (fibrosis) in bon
Slide 6: Total symptom score over time
Total symptom score over time Substantial reduction in TSS observed in the majority of patients1 100 For personal use only Week 12 • 8/13 pts (62%) reached TSS50 up Week 24 to Week 38 Week 38 • Improvement in TSS continue 50 TSS Change from Baseline (%) over time 11 • TSS improvement despite a prior
Slide 7: Spleen volume over time
Spleen volume over time Additional reductions seen with longer treatment1 50 45 Week 12 For personal use only 40 * Week 24 • 11/13 pts had spleen volumes at 35 Week 38 baseline > 450 cm3 30 * 25 Spleen Volume Change % • 9/11 pts (82%) had either stable or 20 15 reduced spleen volume 10 1353 Baseline
Slide 8: Conclusions
Conclusions Interim data1 suggests SNT-5505 combined with ruxolitinib may deliver deep and long lasting benefit to patients who are sub-optimally controlled on ruxolitinib alone For personal use only Consistent with Despite the relatively Reductions in Additional data from monotherapy data2, small s
Slide 9: Targeting multiple near term opportunities in high value markets
Targeting multiple near term opportunities in high value markets For personal use only Anticipated Upcoming Addressable market Drug Candidate Indication Phase Milestones (US$) Interim 12 month data Myelofibrosis Phase 2 ~$1 billion1 June 2025 SNT-5505 Myelodysplastic Syndrome Low & intermediate Risk
Slide 10: Recent & anticipated news flow
Recent & anticipated news flow Strong and growing pipeline with advancement in studies expected to provide value inflection points Key Event For personal use only • Latest phase 2a COMPLETED Q1 2025 June 2025 Q2 2025 Mid 2025 9/12 month Q4 2024 myelofibrosis data SNT-5505 Phase 2a Syntara skin SNT-5
Slide 11: Gary Phillips, Chief Executive Officer
For personal use only Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au www.syntaraTX.com.au